They propose that decreased adiponectin may be a surrogate marker of the pathological process in Alzheimer’s Disease, linking clinical comorbidities, inflammation and cognitive dysfunction. This evidence concerns the gene ADIPOQ and early-onset autosomal dominant Alzheimer disease.